- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03181893
A Study In Adults With Moderate To Severe Dermatomyositis
A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tuebingen, Germany, 72076
- Universitaetsklinikum Tuebingen
-
-
-
-
Hajdú-bihar
-
Debrecen, Hajdú-bihar, Hungary, H-4032
- University of Debrecen
-
-
-
-
-
Bialystok, Poland, 15-707
- Nova Reuma Spolka Partnerska
-
Krakow, Poland, 30-363
- Centrum Medyczne Plejady
-
-
-
-
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Sevilla, Spain, 41010
- Hospital Quiron Infanta Luisa
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
Birmingham, Alabama, United States, 35294
- The University of Alabama at Birmingham
-
Birmingham, Alabama, United States, 35249
- The University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Arizona Research Pharmacy
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic
-
-
California
-
Beverly Hills, California, United States, 90211
- Attune Health Research Inc.
-
Palo Alto, California, United States, 94304
- Freidenrich Center for Translational Research at Stanford University
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Florida
-
Miami, Florida, United States, 33125
- University of Miami Hospital
-
Miami, Florida, United States, 33136
- University of Miami Hospital Clinical Translational Research Site (Infusion site)
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- KU Clinical Research Center - Clinical and Translational Science Unit (CTSU)
-
Kansas City, Kansas, United States, 66160
- The University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21224-6821
- Johns Hopkins Bayview Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital - ACC
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital - CTC
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital - CTH
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Clinical Research Unit (CRU)
-
Minneapolis, Minnesota, United States, 55455
- Lillehei Clinical Research Unit (LCRU)
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota, Department of Dermatology
-
Minneapolis, Minnesota, United States, 55455
- Department of Medicine Division of Rheumatic and Autoimmune Disease
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Health Rheumatology Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63108
- Center for Outpatient Health
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
New York, New York, United States, 10016
- NYU Langone Health Clinical Research Center
-
New York, New York, United States, 10028
- Mount Sinai Doctors Dermatology
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
Portland, Oregon, United States, 97239
- OHSU, Center for Health and Healing CHH2
-
Portland, Oregon, United States, 97239
- Oregon Clinical & Translational Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Texas
-
Dallas, Texas, United States, 75390-9191
- University of Texas Southwestern Medical Center
-
-
Utah
-
Murray, Utah, United States, 84107
- University of Utah MidValley Dermatology
-
Salt Lake City, Utah, United States, 84108
- Center for Clinical & Translational Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Patients with Skin Predominant Activity:
- Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (eg, corticosteroids).
Confirmation of DM by the investigator and two of the following:
- Gottron's papules;
- Gottron's sign;
- Heliotrope eruption;
- Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;
- Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;
- Positive DM serology -
- Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study.
- Willing to provide 8 biopsies during the course of the research study
Inclusion Criteria for Patients with Muscle Predominant Activity:
- MMT-8 ≤136/150 and PhGA, VAS ≥3 cm (0-10 cm) by visual analog scale (VAS)
Sum of PhGA, VAS, PtGA, and extramuscular global assessment VAS scores is ≥10 cm (0-10 cm) VAS for each.
- Participant has failed at least two or more adequate courses of an immunosuppressive agent or immunomodulatory agent, including IVIG, at a dose known to be effective for rheumatologic diseases.
Exclusion Criteria for Patients with Skin Predominant Activity:
- Investigator site staff or members of their family.
- Acute and Chronic present medical conditions
- Intake of greater than 15 mg of prednisone or equivalent per day
- Pregnant or breastfeeding females. Fertile men and women who will not comply with the use of 2 effective birth control methods as per the research protocol
- Have required management of acute or chronic infections
- Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits.
- Clinically significant lab abnormalities
- Any health condition that may be worsened by immunosuppression
Exclusion Criteria for Patients with Muscle Predominant Activity:
Similar to patients with skin predominant activity; Intake of >20 mg oral prednisone/day, or equivalent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo ARM
|
Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
|
Experimental: PF-06823859 ARM high
|
A humanized immunoglobulin neutralizing antibody
|
Experimental: PF-06823859 ARM low
|
A humanized immunoglobulin neutralizing antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2)
Time Frame: Baseline and Week 12
|
The treatment effect was defined as the difference (mean chg from baseline at Week12 in the active treatment group minus that in the placebo group) in the mean change of CDASI activity score from baseline at Week 12.
The score (range: 0-100) consists of the extent score (ES), Gottorn hands score (GHS), peringual score (PS) and allopecia score (AS).
ES (range: 0-90) was obtained by summing up scores for the total erythema (ER [0-45], redness of the skin or mucous membranes), scaling (SC [0-30], peeling of the skin) and erosion/ulceration (EU [0-15], presence of the deeper wound).
Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body.
GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1).
PS (0-2) characterizes abnormalities around nails.
The AS (0-1) characterizes hair loss.
Higher scores indicate greater disease severity.
|
Baseline and Week 12
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3)
Time Frame: Up to Week 40
|
Adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.
AEs included both serious (if occurred) and all non-serious adverse events.
TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.
|
Up to Week 40
|
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3)
Time Frame: Up to Week 40
|
Hemoglobin(HGB),hematocrit,erythrocytes(ery.),HDL cholesterol(chl.)<0.8*lower
limit of normal(LLN);reticulocytes (ret.), ret./ery.(%)<0.5*LLN,>1.5*upper
limit of normal (ULN);ery.
mean corpuscular(EMC) volume,EMC HGB concentration,potassium,chloride,calcium,bicarbonate<0.9*LLN,>1.1*ULN;platelets<0.5*LLN,>1.75*ULN;
leukocytes(leu.),glucose<0.6*LLN,>1.5*ULN;lymphocytes(lym.), lym./leu.(%),neutrophils
(neu.), neu./leu.(%),
protein,albumin<0.8*LLN,>1.2*ULN;basophils(bas.), bas./leu.(%),
eosinophils(eos.),
eos./leu., monocytes(mon.), mon./leu.(%),
urate>1.2*ULN;bilirubin
(total, direct,indirect)>1.5*ULN;aspartate/alanine
aminotransferase,gamma glutamyl transferase,lactate dehydrogenase,alkaline phosphatase>3.0*ULN;urea
nitrogen,creatinine,triglycerides, chl.>1.3*ULN; sodium <0.95*LLN,>1.05*ULN;
creatine kinase >2.0*ULN;Urine: pH<4.5,>8;glucose,
ketones,protein, HGB,urobilinogen,bilirubin,nitrite,leukocyte esterase>=1;ery., leu.>= 20;hyaline casts>1;bacteria>20.
|
Up to Week 40
|
Number of Participants With Vital Sign Abnormalities (Stage 3)
Time Frame: Baseline up to Week 40
|
Abnormality in vital signs: Sitting pulse rate <40 beats per minute (bpm) to >120 bpm, sitting diastolic blood pressure (DBP) < 50 millimeter of mercury (mmHg), sitting systolic blood pressure (SBP) <90 mmHg.
|
Baseline up to Week 40
|
Number of Participants With Electrocardiogram (ECG) Abnormalities (Stage 3)
Time Frame: Baseline up to Week 40
|
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): >450, >480, >500, increase from baseline >=30, increase from baseline >=60; 2) Pulse rate (PR) (msec): >=300, change from baseline (Chg) >=25% or 50%; 3) QT (msec): >=500; 4) QRS (msec): >=200, Chg >=25% or 50%.
Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
|
Baseline up to Week 40
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With TEAEs and SAEs (Stage 1 and Stage 2)
Time Frame: Up to Week 28
|
AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.
AEs included both serious (if occurred) and all non-serious adverse events.
TEAEs are events between first dose of study drug and up to Week 28 that were absent before treatment or that worsened relative to pretreatment state.
|
Up to Week 28
|
Number of Participants With TEAEs and SAEs (Amended Stage 2)
Time Frame: Up to Week 40
|
AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.
SAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.
AEs included both serious (if occurred) and all non-serious adverse events.
TEAEs are events between first dose of study drug and up to Week 40 that were absent before treatment or that worsened relative to pretreatment state.
|
Up to Week 40
|
Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 1 and Stage 2)
Time Frame: Up to Week 28
|
HGB,hematocrit,ery.,HDL chl.<0.8*LLN;ret., ret./ery.
(%)<0.5*LLN,>1.5*ULN;EMC
volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate<0.9*LLN,>1.1*ULN;platelets<0.5*LLN,>1.75*ULN;leu.,glucose<0.6*LLN,>1.5*ULN;lym., lym./leu.(%),
neu., neu./leu.
(%), protein,albumin <0.8*LLN,>1.2*ULN;bas., bas./leu.(%),
eos., eos./leu., mon., mon./leu.(%),
urate >1.2*ULN;bilirubin (total, direct, indirect)>1.5*ULN;aspartate/alanine
aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase>3.0*ULN;urea
nitrogen, creatinine, triglycerides, chl.>1.3*ULN; sodium <0.95*LLN,>1.05*ULN;
creatine kinase >2.0*ULN;Urine: pH<4.5,>8;glucose,
ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase>=1;ery., leu.>= 20;hyaline casts>1;bacteria>20.
Clinical significance of laboratory parameters was determined at the investigator's discretion.
|
Up to Week 28
|
Number of Participants With Clinically Significant Laboratory Abnormalities (Amended Stage 2)
Time Frame: Up to Week 40
|
HGB,hematocrit,ery.,HDL chl.<0.8*LLN;ret., ret./ery.
(%)<0.5*LLN,>1.5*ULN;EMC
volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate<0.9*LLN,>1.1*ULN;platelets<0.5*LLN,>1.75*ULN;leu.,glucose<0.6*LLN,>1.5*ULN;lym., lym./leu.(%),
neu., neu./leu.
(%), protein,albumin <0.8*LLN,>1.2*ULN;bas., bas./leu.(%),
eos., eos./leu., mon., mon./leu.(%),
urate >1.2*ULN;bilirubin (total, direct, indirect)>1.5*ULN;aspartate/alanine
aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase>3.0*ULN;urea
nitrogen, creatinine, triglycerides, chl.>1.3*ULN; sodium <0.95*LLN,>1.05*ULN;
creatine kinase >2.0*ULN;Urine: pH<4.5,>8;glucose,
ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase>=1;ery., leu.>= 20;hyaline casts>1;bacteria>20.
Clinical significance of laboratory parameters was determined at the investigator's discretion.
|
Up to Week 40
|
Number of Participants With Vital Sign Abnormalities (Stage 1 and Stage 2)
Time Frame: Up to Week 28
|
Abnormality in vital signs: Sitting pulse rate <40 bpm to >120 bpm, sitting DBP < 50 mmHg, sitting SBP <90 mmHg.
|
Up to Week 28
|
Number of Participants With Vital Sign Abnormalities (Amended Stage 2)
Time Frame: Up to Week 40
|
Abnormality in vital signs: Sitting pulse rate <40 bpm to >120 bpm, sitting DBP < 50 mmHg, sitting SBP <90 mmHg.
|
Up to Week 40
|
Number of Participants With ECG Abnormalities (Stage 1 and Stage 2)
Time Frame: Up to Week 28
|
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): >450, >480, >500, increase from baseline >=30, increase from baseline >=60; 2) Pulse rate (PR) (msec): >=300, change from baseline (Chg) >=25% or 50%; 3) QT (msec): >=500; 4) QRS (msec): >=200, Chg >=25% or 50%.
Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
|
Up to Week 28
|
Number of Participants With ECG Abnormalities (Amended Stage 2)
Time Frame: Up to Week 40
|
ECG abnormalities criteria included: 1) QTc interval adjusted according to Fridericia formula (QTcF) (msec): >450, >480, >500, increase from baseline >=30, increase from baseline >=60; 2) Pulse rate (PR) (msec): >=300, change from baseline (Chg) >=25% or 50%; 3) QT (msec): >=500; 4) QRS (msec): >=200, Chg >=25% or 50%.
Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
|
Up to Week 40
|
Change From Baseline in CDASI Activity Score at at All Scheduled Timepoints Through Week 12 (Stage 1, Stage 2 and Amended Stage 2)
Time Frame: Baseline, Week 1, Week 4, and Week 8 (except for Week 12 which is a primary outcome measure)
|
The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints.
The score (range: 0-100) consists of the ES, GHS, PS and AS.
ES (range: 0-90) was obtained by summing up scores for the total erythema (ER [0-45], redness of the skin or mucous membranes), scaling (SC [0-30], peeling of the skin) and erosion/ulceration (EU [0-15], presence of the deeper wound).
Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body.
GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1).
PS (0-2) characterizes abnormalities around nails.
The AS (0-1) characterizes hair loss.
Higher scores indicate greater disease severity.
|
Baseline, Week 1, Week 4, and Week 8 (except for Week 12 which is a primary outcome measure)
|
Change From Baseline in CDASI Activity Score at All Scheduled Timepoints Through Week 12 (Stage 3)
Time Frame: Baseline, Week 1, Week 4, Week 8 and Week 12
|
The treatment effect was defined as the difference (mean change from baseline at Weeks 1, 4, 8,12 in the active treatment group minus the mean change from baseline at Weeks 1, 4, 8, 12 in the placebo group) in the mean change of CDASI activity score from baseline at scheduled timepoints.
The score (range: 0-100) consists of the ES, GHS, PS and AS.
ES (range: 0-90) was obtained by summing up scores for the total erythema (ER [0-45], redness of the skin or mucous membranes), scaling (SC [0-30], peeling of the skin) and erosion/ulceration (EU [0-15], presence of the deeper wound).
Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body.
GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1).
PS (0-2) characterizes abnormalities around nails.
The AS (0-1) characterizes hair loss.
Higher scores indicate greater disease severity.
|
Baseline, Week 1, Week 4, Week 8 and Week 12
|
Absolute Values of CDASI Activity Score at All Scheduled Timepoints Through Week 12 (All Stages)
Time Frame: Baseline, Week 1, Week 4, Week 8 and Week 12
|
The CDASI activity score (range: 0-100) consists of the ES, GHS, PS and AS.
ES (range: 0-90) was obtained by summing up scores for the total erythema (ER [0-45], redness of the skin or mucous membranes), scaling (SC [0-30], peeling of the skin) and erosion/ulceration (EU [0-15], presence of the deeper wound).
Total ER, SC and EU scores were calculated as a sum of the contributions from 15 individual areas of the body.
GHS characterizes papules (swellings) on hand and is a sum of the papule's characterization score (0-6) and ulceration score (0-1).
PS (0-2) characterizes abnormalities around nails.
The AS (0-1) characterizes hair loss.
Higher scores indicate greater disease severity.
|
Baseline, Week 1, Week 4, Week 8 and Week 12
|
Absolute Values of CDASI Damage Score at All Scheduled Timepoints Through Week 12 (All Stages)
Time Frame: Baseline, Week 1, Week 4, Week 8 and Week 12
|
The Damage Score (DS) was calculated as a sum of the total poilkiloderma score (POLS), total calcinosis score (CALS) and Gotorn's hands damage score (GHDS).
The POLS characterizes specific dispigmentation in the particulal area and calcinosis score characterizes calcification of the skin in the particular area.
The POLS and the CALS are summed up over 15 individual areas in the body and each of them has range 0-15.
The GHDS has the range 0-2 so that the DS has the range 0-32.
Higher scores indicate greater disease severity.
|
Baseline, Week 1, Week 4, Week 8 and Week 12
|
Absolute Values for Total Improvement Score (TIS) at Week 12 and Intermediate Scheduled Time Points (Stage 3)
Time Frame: Week 4, Week 8 and Week 12
|
The TIS was the sum of all 6 improvement scores where higher score indicates worse status (PhGA [from the MDAAT, 0-20 scale], PtGA [0-10 scale], MMT [0-35 scale], HAQ-DI [0-10 scale], muscle enzymes [0-7.5 scale], and extramuscular global assessment [0-20 scale]) associated with the change in each core set measure.
A total improvement score between 0 and 100 corresponded to the degree of improvement, with higher scores corresponding to a greater degree of improvement: of ≥20 represented minimal improvement, a score of ≥40 represented moderate improvement, and a score of ≥60 represented major improvement.
|
Week 4, Week 8 and Week 12
|
Change From Baseline in the Core Set Measures (CSM) of the TIS (Global Disease Activity [PhGA] and Extramuscular Global Assessment [EmGA]) (Stage 3)
Time Frame: Baseline, Week 4, Week 8 and Week 12
|
PhGA: assessment of the severity of disease by the physician. The physician used the visual analog scale and put a mark on 0 cm (best) -10 cm (worst) scale where higher score indicated worse status. EmGA: overall evaluation of disease activity in all extramuscular systems using visual analog scale 0 cm (best) -10 cm (worst) scale where higher score indicated worse status. |
Baseline, Week 4, Week 8 and Week 12
|
Change From Baseline in the CSM of the TIS (PtGA) (Stage 3)
Time Frame: Baseline, Week 4, Week 8 and Week 12
|
PtGA: assessment of the severity of disease by the participant/participant's guardian, using a visual analog scale from 0 mm (no evidence of disease activity) to 100 mm (extremely active or severe disease activity).
Higher score indicated worse status.
|
Baseline, Week 4, Week 8 and Week 12
|
Change From Baseline in the CSM of the TIS (MMT8 and HAQ01-HAQ-DI) (Stage 3)
Time Frame: Week 4, Week 8 and Week 12
|
Manual Muscle Testing-8 designated muscle groups (MMT-8): was a set of 8 designated muscles tested unilaterally generally on right side (left side used unless right side cannot be used). Potential score range was from 0 to 80, where higher scores denoted better health status. HAQ-DI: contained eight sections (including dressing & grooming, arising, eating, walking, hygiene, grip, reach, and activities). Each section had multiple questions that the participant used to rank their functionality and ranged from 0 to 3 where 0 = without any difficulty and 3 = unable to do. For each participant, the average ranking was calculated for each of the eight sections. HAQ-DI had a score range of 0 to 3, where higher score reflected worse status. |
Week 4, Week 8 and Week 12
|
Change From Baseline in the CSM of the TIS (Aldolase and Creatine Kinase) (Stage 3)
Time Frame: Baseline, Week 4, Week 8 and Week 12
|
The LS mean (with 90% CI) of CSM of the TIS (aldolase and creatine kinase) at weeks 4, 8, 12 were presented.
|
Baseline, Week 4, Week 8 and Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C0251002
- 2020-004228-41 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatomyositis
-
Istituto Giannina GasliniPediatric Rheumatology International Trials OrganizationCompletedJuvenile DermatomyositisItaly
-
The First Hospital of Jilin UniversityCompletedJuvenile Dermatomyositis
-
The Cleveland ClinicMallinckrodtCompletedDermatomyositis | Juvenile DermatomyositisUnited States
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingDermatomyositis, Adult Type
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingDermatomyositis, Adult TypeChina
-
Tulane UniversityCompletedDermatomyositis, Adult TypeUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile DermatomyositisFrance
-
The Hospital for Sick ChildrenCompletedJuvenile DermatomyositisCanada
-
Second Affiliated Hospital, School of Medicine,...RecruitingGastric Mucosal Manifestations in Patients With DermatomyositisChina
-
MedImmune LLCCompletedDERMATOMYOSITIS OR POLYMYOSITISUnited States
Clinical Trials on Placebo Arm
-
IVIEW Therapeutics Inc.CompletedAdenoviral ConjunctivitisIndia
-
Chr HansenCompleted
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UrticariaUnited States, Belgium, United Kingdom, Germany, Hungary, Spain, France, Turkey, Canada, Czechia, Netherlands, Poland, Japan, Russian Federation, Argentina, Denmark, Slovakia
-
French Innovative Leukemia OrganisationNovartis PharmaceuticalsActive, not recruiting
-
Gangnam Severance HospitalRecruiting
-
Kanyos Bio, Inc., a wholly-owned subsidiary of...PfizerRecruitingCeliac Disease | Coeliac DiseaseUnited States, Canada
-
Infinity Pharmaceuticals, Inc.CompletedConventional ChondrosarcomaUnited States, Italy, Canada, Austria, Australia, Germany, France, Netherlands, Norway, Poland, Russian Federation, Sweden, United Kingdom
-
Gangnam Severance HospitalRecruitingPancretic Dissease (Benign/Malignancy) | BIle Duct Diseae(Benign/Malignancy) | Ampulla of Vater Disease (Benign/Malignancy)Korea, Republic of
-
CD Pharma India Pvt. Ltd.Government Dental College and Hospital, Vijayawada, Andra Pradesh, IndiaCompletedMild and Moderate Chronic PeriodontitisIndia
-
PfizerTrans Tech PharmaceuticalsCompletedAlzheimer DiseaseUnited States